C-QF1Rgeneric medicines, specialty medicines, AI drug discovery
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Algorae states that drug development is changing and that the company aims to evolve with it by developing transformative solutions for significant unmet medical needs. It says advanced artificial intelligence and computational tools can analyze large, disparate datasets to identify therapeutic drug targets and improve understanding of existing therapeutic assets, while collaborations with leading organizations are intended to create long-term shareholder value and advance its research and development programs.
SourceAlgorae states that drug development is evolving and that it is developing transformative solutions for significant unmet medical needs. The company believes patient access to novel drugs and therapies can be accelerated by using advanced artificial intelligence and scientific innovation to analyze large disparate datasets, identify therapeutic drug targets, and improve understanding of existing therapeutic assets, while creating long-term shareholder value through collaboration with leading organizations.
SourceAlgorae states that drug development is changing and that the company is changing with it, presenting itself as a clinical-stage pharmaceutical company focused on developing transformative solutions for significant unmet medical needs in the community.
Source